First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
Open Access
- 11 July 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Esophagus
- Vol. 51 (3), 241-251
- https://doi.org/10.1007/s00535-015-1102-z
Abstract
Infliximab (IFX) is one of the treatments of choice for corticosteroid-refractory and corticosteroid-dependent ulcerative colitis (UC). A high serum trough level of IFX (TL) is reported to be associated with sustained efficacy during maintenance treatment. As part of a phase 3 randomized controlled trial of IFX in UC, we assessed the predictive value of the first TL at week 2 for short- and long-term response.Keywords
This publication has 30 references indexed in Scilit:
- Anti-infliximab antibodies in inflammatory bowel diseaseEuropean Journal of Gastroenterology & Hepatology, 2012
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative ColitisGastroenterology, 2011
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2011
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut, 2009
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid TherapyNew England Journal of Medicine, 1994
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987